Onclive Team

Articles

Atezolizumab Plus Bevacizumab Impresses in Unresectable HCC

September 28th 2019

Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.

Selinexor Improves Late-Stage Treatment Options for Multiple Myeloma

September 25th 2019

Sundar Jagannath, MBBS, discusses the significance the selinexor (Xpovio) approval has for patients with myeloma, the tolerability of the agent, and the management of related adverse events.

Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena

September 25th 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.

City of Hope Shares Topline Updates

September 23rd 2019

City of Hope shares recent research grants and awards given to faculty at the institution.

ISGIO Presents 16th Annual Gastrointestinal Oncology Conference

September 17th 2019

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

Ochsner and Statewide Partners Awarded $13.6 Million NCI Grant

September 16th 2019

Ochsner Cancer Institute (Ochsner), along with its Gulf South NCI Community Oncology Research Program (NCORP) partners, has been awarded a $13.6 million grant by the National Cancer Institute to expand the successful statewide clinical trials network with a special emphasis on minority and underserved cancer patients.

Liquid Biopsy Matches Tissue for NSCLC Treatment Guidance

September 12th 2019

Patients with advanced non–small cell lung cancer and actionable mutations had similar progression-free survival whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.

Gaining Ground in GI Cancers in Denver

September 11th 2019

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

Mutation-Defined Lung Cancer Trial Yields Hits and Misses for Targeted Therapy

September 11th 2019

Targeted therapies for non–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

Selpercatinib Achieves High Response Rate in RET+ NSCLC

September 10th 2019

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

Durvalumab Combo Improves Survival in Frontline Small Cell Lung Cancer

September 9th 2019

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer

September 9th 2019

Findings from a small case series of patients with lung cancer added to evidence that afatinib is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions.

Bemcentinib/Pembrolizumab Combo Active in Chemo-Refractory NSCLC

September 9th 2019

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

AMG 510 Highly Active in KRAS+ NSCLC

September 8th 2019

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

Mapping Multiple Myeloma Advances in NYC

September 4th 2019

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

Garnering Breakthroughs in GU Cancers in Boston

August 29th 2019

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the faculty from the Dana-Farber Cancer Institute.

Largest Study of Prostate Cancer in African American Men Recruiting Participants

August 28th 2019

The group of researchers is conducting the largest African-American prostate cancer study ever, aiming to include 10,000 men nationwide.

Roswell Park Neurosurgeon Honored by Professional Society

August 28th 2019

Dr. Andrew Fabiano included in Spine Society's 20 Under 40, also named an ABNS guest examiner.

Baylor Awarded CPRIT Grants to Support Cancer Research

August 26th 2019

Baylor College of Medicine has been awarded more than $17.4 million by the Cancer Prevention & Research Institute of Texas to support new cancer research and programs, core facilities and recruitment of new faculty.

Benson Cancer Center Earns National Re-Accreditation with Commendation from the Commission on Cancer of the American College of Surgeons

August 23rd 2019

The Gayle and Tom Benson Cancer Center at Ochsner Medical Center (Benson Cancer Center) has again been granted Three-Year Accreditation with Commendation from The Commission on Cancer, a quality program of the American College of Surgeons.